Similar articles

• [Optimizing treatment of complicated forms of inflammatory bowel disease. Fistulizing Crohn's disease].

  Peñate M, Cruz-Santamaría M, Mendoza JL, Peña AS, Díaz-Rubio M, García-Paredes J. Peñate M, et al. An Med Interna. 2003 Jan;20(1):37-45. An Med Interna. 2003. PMID: 12666309 Review. Spanish. No abstract available.
• Refractory enterovesical and duodenocolic fistulas in Crohn's disease successfully managed with tacrolimus.

  Fukuda A, Nakase H, Seno H, Nabeshima M, Sawada M, Chiba T. Fukuda A, et al. J Gastroenterol. 2005 Apr;40(4):433-5. doi: 10.1007/s00535-004-1564-x. J Gastroenterol. 2005. PMID: 15870981 No abstract available.
• Type of fistula determines response to infliximab in patients with fistulous Crohn's disease.

  Parsi MA, Lashner BA, Achkar JP, Connor JT, Brzezinski A. Parsi MA, et al. Am J Gastroenterol. 2004 Mar;99(3):445-9. doi: 10.1111/j.1572-0241.2004.04083.x. Am J Gastroenterol. 2004. PMID: 15056083
• [Enterovesical fistula in Crohn disease. An infrequent presentation].

  Quintero Rodríguez R, Guerrero Jiménez P, Vilches Cocovi E, Sánchez Blanco JM, García Pérez M. Quintero Rodríguez R, et al. Arch Esp Urol. 1994 Jun;47(5):531-2. Arch Esp Urol. 1994. PMID: 7944591 Spanish.
• Review article: Medical therapy for fistulizing Crohn's disease.

  Bressler B, Sands BE. Bressler B, et al. Aliment Pharmacol Ther. 2006 Nov 1;24(9):1283-93. doi: 10.1111/j.1365-2036.2006.03126.x. Aliment Pharmacol Ther. 2006. PMID: 17059510 Review.